IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy
Nature Genetics2009Vol. 41(10), pp. 1100–1104
Citations Over TimeTop 1% of 2009 papers
for the Hepatitis C Study, Vijayaprakash Suppiah, Max Moldovan, Golo Ahlenstiel, Thomas Berg, Martin Weltman, Maria Lorena Abate, Margaret F. Bassendine, Ulrich Spengler, Gregory J. Dore, Elizabeth E. Powell, Stephen M. Riordan, David Sheridan, Antonina Smedile, Vincenzo Fragomeli, Tobias Müller, Melanie Bahlo, Graeme J. Stewart, David Booth, Jacob George
Related Papers
- → Pegylated interferon plus ribavirin versus non-pegylated interferon plus ribavirin for chronic hepatitis C(2009)18 cited
- → Pegylated interferon plus ribavirin versus non-pegylated interferon plus ribavirin for chronic hepatitis C(2005)5 cited
- → 576 Early detection of depressive symptoms during treatment with pegylated interferon α-2 and ribavirin in euthymic chronic hepatitis C patients(2006)
- → Dermatological Side Effects in a Patient with Hepatitis C Infection During Treatment with Pegylated Interferon/Ribavirin+Telaprevir: A Case Report(2014)
- → Pegylated Interferon, Ribavirin, and Sofosbuvir Combination versus Pegylated Interferon, Ribavirin in the Management of Chronic Hepatitis C Egyptian Patients(2017)